 By David Bautz, PhD NASDAQ:BCLI READ THE FULL BCLI RESEARCH REPORT Business Update Topline Data from Phase 3 ALS Trial Before End of November 2020 BrainStorm Cell Therapeutics, Inc. NASDAQ:BCLI is currently conducting a Phase 3 clinical trial of NurOwn in patients with amyotrophic lateral sclerosis ALS NCT03280056 . A total of 200 patients were randomized 1:1 to receive NurOwn or placebo 